CG Oncology, Inc. Common stock (CGON) Stock
NASDAQ · CGON
Key stats
- Market cap
- $6.49B
- Price / Earnings ratio
- -27.3x
- EPS (TTM)
- -$2.76
- Volume
- Loading
- 52-week high
- $80.97
- 52-week low
- $35.80
Source: third-party data provider, as of November 13, 2026
Compare with CGON
Recent news

Zacks Investment Research
CG Oncology, Inc. (CGON) Reports Q2 Loss, Misses Revenue Estimates
CGONAugust 6, 2026
Zacks Investment Research
CG Oncology, Inc. (CGON) Reports Q2 Loss, Misses Revenue Estimates
CGON

Stocktwits
Biotech Stocks Need A Shot In The Arm After Brutal July: Could AstraZeneca-Bristol Myers Megadeal Be The Cure?
CGONAugust 3, 2026
Stocktwits
Biotech Stocks Need A Shot In The Arm After Brutal July: Could AstraZeneca-Bristol Myers Megadeal Be The Cure?
CGON

Zacks Investment Research
CG Oncology Stock Gains 12% in Three Months: What's Driving It?
CGONJuly 13, 2026
Zacks Investment Research
CG Oncology Stock Gains 12% in Three Months: What's Driving It?
CGON

MarketBeat
CG Oncology Eyes Bladder Cancer Breakthrough With Phase 3 Data, Q4 Filing Ahead
CGONJune 10, 2026
MarketBeat
CG Oncology Eyes Bladder Cancer Breakthrough With Phase 3 Data, Q4 Filing Ahead
CGON
Technical indicators
- RSI 14
- 60.35
- MACD 12/26/9
- 1.56
- EMA 9 of MACD
- 0.01
- MACD histogram
- 1.55
- SMA 50
- $68.13
- Price above SMA 50
- EMA 50
- $67.82
- Price above EMA 50
- SMA 200
- $66.49
- Price above SMA 200
- EMA 200
- $63.38
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 2 analyst ratings
Strong Sell0
Sell0
Hold0
Buy2
Strong Buy0
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Revenue
Net income
Net margin %
2021
2022
2023
2024
2025
12M8M4M0
Debt & Balance Sheet
Total assets
Total liabilities
2021
2022
2023
2024
2025
950M627M313M0
Revenue to Profit
2025$4.0M
Revenue$0.0
Cost of revenue$-607000.0
Gross profit$0.0
Operating expenses$-161.0M
Net incomeEarnings
No data available
Source: third-party data provider
Latest news

Zacks Investment Research
CG Oncology, Inc. (CGON) Reports Q2 Loss, Misses Revenue Estimates
CGONAugust 6, 2026
Zacks Investment Research
CG Oncology, Inc. (CGON) Reports Q2 Loss, Misses Revenue Estimates
CGON

Stocktwits
Biotech Stocks Need A Shot In The Arm After Brutal July: Could AstraZeneca-Bristol Myers Megadeal Be The Cure?
CGONAugust 3, 2026
Stocktwits
Biotech Stocks Need A Shot In The Arm After Brutal July: Could AstraZeneca-Bristol Myers Megadeal Be The Cure?
CGON

Zacks Investment Research
CG Oncology Stock Gains 12% in Three Months: What's Driving It?
CGONJuly 13, 2026
Zacks Investment Research
CG Oncology Stock Gains 12% in Three Months: What's Driving It?
CGON

MarketBeat
CG Oncology Eyes Bladder Cancer Breakthrough With Phase 3 Data, Q4 Filing Ahead
CGONJune 10, 2026
MarketBeat
CG Oncology Eyes Bladder Cancer Breakthrough With Phase 3 Data, Q4 Filing Ahead
CGON

MarketBeat
CG Oncology Touts Cretostimogene Data, BLA Progress in Bladder Cancer Push
CGONJune 7, 2026
MarketBeat
CG Oncology Touts Cretostimogene Data, BLA Progress in Bladder Cancer Push
CGON

MarketBeat
CG Oncology Touts Bladder Cancer Data, Q4 Filing Plans at RBC Conference
CGONMay 21, 2026
MarketBeat
CG Oncology Touts Bladder Cancer Data, Q4 Filing Plans at RBC Conference
CGON

MarketBeat
CG Oncology BLA Filing on Track as Key Bladder Cancer Data Nears
CGONMay 15, 2026
MarketBeat
CG Oncology BLA Filing on Track as Key Bladder Cancer Data Nears
CGON

Zacks Investment Research
CG Oncology, Inc. (CGON) Reports Q1 Loss, Tops Revenue Estimates
CGONMay 8, 2026
Zacks Investment Research
CG Oncology, Inc. (CGON) Reports Q1 Loss, Tops Revenue Estimates
CGON

Zacks Investment Research
Wall Street Analysts Think CG Oncology, Inc. (CGON) Could Surge 29.78%: Read This Before Placing a Bet
CGONMay 5, 2026
Zacks Investment Research
Wall Street Analysts Think CG Oncology, Inc. (CGON) Could Surge 29.78%: Read This Before Placing a Bet
CGON

Zacks Investment Research
CG Oncology, Inc. (CGON) Upgraded to Buy: Here's What You Should Know
CGONMay 1, 2026
Zacks Investment Research
CG Oncology, Inc. (CGON) Upgraded to Buy: Here's What You Should Know
CGON
About CG Oncology, Inc. Common stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees142
CEOMr. Arthur Kuan
IPO DateJan 25, 2024
HeadquartersDallas, TX
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Arthur Kuan | President, Chairman & CEO | 1991 |
| Mr. James M. DeTore | Chief Financial Officer | 1965 |
| Mr. Joshua F. Patterson | General Counsel, Chief Compliance Officer & Secretary | 1977 |
| Dr. Vijay Kasturi M.D. | Chief Medical Officer | 1968 |
| Mr. Swapnil Bhargava Ph.D. | Chief Technical Officer | — |
| Ms. Amy Steele | Vice President of Finance & Administration | — |
| Ms. Sarah Connors | Vice President of Communications & Patient Advocacy | — |
| Mr. Bing Kung | Vice President of Corporate Development | — |
Fundamentals
Valuation
Price-to-sales ratio2,984.41
Price-to-book value6.55
Profitability
Return on Equity-25.00%
Return on Assets-24.00%
Return on Sales-3603.00%
Gross margin (latest quarter)-66.40%
EBITDA$-221.36M
Trading
Average volume1,085,637
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 60.35
- MACD 12/26/9
- 1.56
- EMA 9 of MACD
- 0.01
- MACD histogram
- 1.55
- SMA 50
- $68.13
- Price above SMA 50
- EMA 50
- $67.82
- Price above EMA 50
- SMA 200
- $66.49
- Price above SMA 200
- EMA 200
- $63.38
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Analyst consensus:Buy
100% Buy
0% Hold
0% Sell
Analyst price target
- Low
- $84.00
- Average
- $86.50
- High
- $89.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | +0.2 | +17.8 | -0.2 | -6.0 | -19.8 | -12.4 | +5.1 | +9.0 | +6.7 | -3.7 | -3.2 | -19.8 |
| 2025 | +3.8 | -11.9 | -2.4 | +22.2 | -7.6 | -2.2 | +1.3 | +1.9 | +46.7 | +9.7 | +7.0 | -4.0 |
| 2026 | +24.6 | +8.2 | +17.2 | -0.1 | -6.0 | +20.0 | +0.4 | +8.7 | -6.6 | -5.4 | +17.2 |
Compare stocks
Market cap
$6.49B
-
-
-
Price / Earnings ratio
-27.30
-
-
-
Price / Sales ratio
2,984.41
-
-
-
Dividend yield
0.00%
-
-
-
Average volume
1,085,637
-
-
-
Earnings per share
$-2.76
-
-
-



